1.
Khalafallah AA, Fernandopulle B, Brain T. Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia. Mediterr J Hematol Infect Dis [Internet]. 2010 May 31 [cited 2024 Mar. 28];2(2):e2010012. Available from: https://www.mjhid.org/mjhid/article/view/2010.012